FULGENT GENETICS INC (FLGT)
Health Care · clinical diagnostics and genetic testing · NASDAQ
Fulgent Genetics is a diagnostic laboratory that leverages proprietary technology to provide accessible, affordable, and actionable genetic testing for rare diseases, cancer, and reproductive health.
What FULGENT GENETICS INC does
Fulgent Genetics is a technology-based diagnostic company that provides comprehensive genetic testing, including next-generation sequencing (NGS) panels and clinical diagnostic services. The company develops and delivers proprietary genetic testing solutions for a broad range of conditions, including rare diseases, oncology, and reproductive health, while also providing biopharmaceutical research services.
Themes: precision medicine, genetic testing / genomics, oncology diagnostics, reproductive health, biotech research services
Fundamentals
- Price$19.90 as of 2026-08-21 close
- Market cap$548M as of 2026-08-21
- 1-year return-7.0% 2025-08-21 close $21.40 → 2026-08-21 close $19.90
- P/En/a negative earnings
- Net margin-26.1% as of 2026-08-24
- Gross margin+35.6% as of 2026-08-24
- ROE-7.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+6.8% as of 2026-08-24
- Revenue CAGR (3y)-19.5% SEC XBRL
- Beta0.97 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How FLGT compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How FULGENT GENETICS INC looks technically
FULGENT GENETICS INC (FLGT) is trading 5.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 107 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 16 trading days ago. It is 35.9% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 5.7% below its 200-day average, the long-term trend line — a long-term downtrend | -5.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $19.42 | $19.42 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $21.10 | $21.10 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 107 trading days ago — a "death cross", a bearish long-term signal | 107 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 18.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 57.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($17.36 to $20.52) — its "stochastic" reading is 80 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 80.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $31.04 | $31.04 |
|---|---|---|
| From the 52-week high | it is 35.9% below its 52-week high (its highest price of the past year) | -35.9% |
| Above the 52-week low | it is 47.8% above its 52-week low (its lowest price of the past year) | +47.9% |
| Below the 52-week high | it is 35.9% below its highest point of the past year | 35.9% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $189.89 (set on 2021-02-09) | $189.89 |
| Given back of the 52-week move | over the past year its closes ranged ($13.79 to $30.85), and it has recovered roughly a third of its fall from last year’s high — 36% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $24.33 to $24.88. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 35.8% |
| From the all-time high | it is 89.5% below its all-time high | -89.5% |
| Nearest price level | it is trading 2.1% below a resistance level at $20.32 — a price it turned at twice since 2025-07-01, most recently on 2026-07-30. Since 2024-08-21 it has 7 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.1% |
| All-time low | its lowest closing price on record is $2.73 (set on 2017-11-07) | $2.73 |
| Above the all-time low | it is 630.3% above its all-time low | +630.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 38th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7474 between its high and its low — about 3.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7474 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $17.26 and $20.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $17.26 – $18.94 – $20.61 |
| Typical daily range (% of price) | its price moves about 3.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.8% |
| Stretch from the 200-day average | it is trading 1.6 daily ranges below its 200-day average price (5.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.14× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Open gap | it gapped 2.1% above the previous close 2 sessions ago and has not traded back through the level it left behind at 18.57 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.1% |
| Gap filled | a 14.3% gap down opened on 2026-07-31 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 14 sessions to close | 1 session ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.2 percentage points (the stock gained 0.1% while the market gained 2.3%) | -2.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.4 percentage points (the stock gained 14.5% while the market gained 3.1%) | +11.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 25.2 percentage points (the stock lost 14.2% while the market gained 11.1%) | -25.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 27.5 percentage points (the stock lost 7.0% while the market gained 20.5%) | -27.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 12.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $17.57 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +13.2% |
|---|---|---|
| Vs the average paid since it last reported | the price is 9% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $18.33 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +8.6% |
Price levels it has turned at before
FLGT last closed at $19.90 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $20.32 | Resistance | 2.1% above the last close | turned there twice · 2025-07-01 to 2026-07-30 |
| $19.34 | Support | 2.8% below the last close | turned there 9 times · 2024-10-10 to 2026-08-10 |
| $18.89 | Support | 5.1% below the last close | turned there twice · 2024-10-24 to 2025-06-23 |
| $20.91 | Resistance | 5.1% above the last close | turned there twice · 2024-09-10 to 2025-05-02 |
| $21.45 | Resistance | 7.8% above the last close | turned there six times · 2024-12-09 to 2026-07-16 |
| $17.57 | Support | 11.7% below the last close | turned there four times · 2024-12-30 to 2026-06-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Just filled a gap (5%+ closed in the last week) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$19.00 range $19.00 – $19.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FLGT
- Consensus EPS estimate-$0.65 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Continued operating losses and potential difficulty in achieving future profitability.","Significant competition in the genetic testing and diagnostic services market.","Dependence on reimbursement from third-party payors and potential for changes in reimbursement policies."]
What changed in the latest 10-Q
AI-assisted comparison of FLGT's 10-Q filed 2026-05-01 against the prior one filed 2025-11-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to fiscal year ended December 31, 2025 and Form 10-K filing date of February 27, 2026 (newer filing, filed 2026-05-01)
- Removed:
- Reference to fiscal year ended December 31, 2024 and Form 10-K filing date of February 28, 2025 (older filing, filed 2025-11-07)
- Mention of 'the development of our drug candidates' in forward-looking statements description (older filing, filed 2025-11-07)
- Reworded:
- Changed '2024 Annual Report' to '2025 Annual Report' (newer filing, filed 2026-05-01)
- Notes:
- Both texts appear truncated at the end; comparison limited to complete portions available
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 4 sells ($106343) — 2 selling insiders
- Last 180 days0 buys · 4 sells ($106343) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-02. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about FLGT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding FLGT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,397,856
- Reported value $54,025,910
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
FLGT had 2,565,192 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
FLGT had 9.32% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8 days to cover at the same settlement.
- Reported short interest (shares) 2,565,192
- Short interest (% of shares outstanding) 9.32%
- Prior settlement (shares) 2,753,798
- Reported change -6.85%
- Days to cover (reported) 8
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Invitae
- Myriad Genetics (MYGN)
- Natera (NTRA)
- Guardant Health (GH)
- Exact Sciences (EXAS)
- Labcorp (LH)
- Quest Diagnostics (DGX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare FLGT vs…
FULGENT GENETICS INC is found in…
FLGT ranks in…
Frequently asked questions
What does FULGENT GENETICS INC (FLGT) do?
Fulgent Genetics is a technology-based diagnostic company that provides comprehensive genetic testing, including next-generation sequencing (NGS) panels and clinical diagnostic services. The company develops and delivers proprietary genetic testing solutions for a broad range of conditions, including rare diseases, oncology, and reproductive health, while also providing biopharmaceutical research services.
What sector is FULGENT GENETICS INC (FLGT) in?
FULGENT GENETICS INC (FLGT) is classified in the Health Care sector. Its industry is clinical diagnostics and genetic testing. It trades on NASDAQ.
Who are FULGENT GENETICS INC's (FLGT) competitors?
Notable peers of FULGENT GENETICS INC (FLGT) include Invitae, Myriad Genetics, Natera, Guardant Health and Exact Sciences. This peer set is informational only — not financial advice.
Is FULGENT GENETICS INC (FLGT) overbought or oversold right now?
FULGENT GENETICS INC (FLGT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on FLGT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.